How to Value a Physical Therapy Group in 2026

Physical therapy is one of the most actively consolidated healthcare services verticals in the country. Between 2018 and 2025, private equity firms deployed billions into PT platform acquisitions — ATI Physical Therapy, Upstream Rehabilitation (now part of Concentra), U.S. Physical Therapy, and dozens of regional platforms. That consolidation wave has created a well-defined market for multi-location PT groups with real EBITDA, and the pricing benchmarks are clearer than in almost any other healthcare services niche.

But the market is also more nuanced than most PT group owners realize. I've seen groups with identical revenue get offers that differ by 3-4x EBITDA because of factors like therapist retention, payer mix, and how well the business functions without the founding clinician. Here's how the valuation actually works.

The Valuation Range: 7-12x EBITDA for Multi-Location Groups

Multi-location physical therapy groups with 5+ clinics and $1.5M+ EBITDA typically sell for 7-12x EBITDA. That's a wide range, and where you fall depends on scale, growth trajectory, and deal structure.

Bolt-on acquisitions — where a PE-backed platform adds your clinics to their existing network — trade at 7-9x EBITDA. The platform already has the corporate infrastructure, billing systems, and management layer. They're buying your patient volume, therapist relationships, and geographic coverage.

Platform acquisitions — where PE firms acquire your group as the foundation for a new regional or national platform — trade at 9-12x EBITDA. These require meaningful scale (typically 10+ locations, $3M+ EBITDA), a proven management team, and a geographic footprint that supports a roll-up strategy. The premium compensates for the infrastructure you've built and the management team that will stay to execute the growth plan.

For context, the public benchmarks are instructive. ATI Physical Therapy was taken private by Advent International at approximately 12x trailing EBITDA. Upstream Rehabilitation was acquired by Concentra (backed by Welsh, Carson, Anderson & Stowe) at a reported 10-11x EBITDA. U.S. Physical Therapy (USPH), a public company, has historically traded at 12-16x EBITDA, reflecting its scale and public market premium. These represent the upper bound, but they anchor buyer expectations across the sector.

Solo clinics and small groups (2-4 locations) are a different market entirely. These sell on SDE at 2-4x to individual therapists or small regional groups. The buyer pool is thinner, the financing is harder, and the multiples reflect it.

Therapist Retention: The Deal Driver Nobody Talks About Enough

In every PT group transaction I've worked on, the single most scrutinized metric during due diligence — more than revenue, more than EBITDA — is therapist retention. Here's why.

A physical therapy clinic's revenue is a direct function of how many therapists are treating and how many visits they generate. The industry standard is 50-65 visits per therapist per week for a productive clinic. Lose a therapist and you lose $300,000-$500,000 in annualized revenue within weeks. Recruiting a replacement takes 60-120 days in most markets, during which that revenue simply evaporates.

The national PT therapist turnover rate runs 25-35% annually, driven by burnout, productivity pressure, and student loan-motivated job-hopping. A group that's running 15-20% annual turnover is meaningfully outperforming the market, and buyers notice. A group running 40%+ turnover is a red flag that can kill a deal outright.

What buyers look for specifically:

• Average therapist tenure: 3+ years is strong. Under 18 months signals a retention problem.
• Non-compete agreements: Enforceable non-competes (varies by state) protect against therapists leaving and opening a practice across the street.
• Compensation structure: Groups that pay competitive base salaries plus productivity bonuses retain better than those that lean heavily on productivity-only models.
• Clinical mentorship programs: New grad retention is dramatically higher in groups that offer structured residency or mentorship tracks.

I've seen therapist retention be the deciding factor in a deal. One group with $2.5M EBITDA and 18% annual turnover received a 10x offer. A comparable group with $2.8M EBITDA but 38% turnover received 7.5x — and the buyer required an earn-out tied to retention metrics. The lower-EBITDA group walked away with a better deal because the buyer had confidence in revenue sustainability.

EBITDA Adjustments: Where PT Group Deals Get Complicated

Physical therapy EBITDA calculation requires more adjustments than most healthcare services businesses, and sophisticated buyers know exactly what to look for.

Owner clinician compensation. If the founding PT still treats patients, you need to normalize their compensation to market rate. A founding owner taking $400K in total comp who also treats 40 patients per week is both an owner (worth $250K in management comp) and a clinician (worth $90K-$120K for the treating role). The EBITDA add-back is only the excess above market — roughly $30K-$60K — not the full owner comp. Buyers who see owners trying to add back their entire salary as an EBITDA adjustment lose trust fast.

Rent normalization. Many PT group owners lease clinic space from entities they personally own. If you're paying yourself above-market rent, buyers will adjust EBITDA upward. If below-market, they'll adjust down. Typical PT clinic rent runs 8-12% of clinic revenue; anything outside that range gets normalized.

Recruiting costs. In a tight labor market, therapist recruiting costs ($8,000-$15,000 per hire including agency fees, sign-on bonuses, and onboarding) can swing EBITDA materially. Buyers will normalize these to a sustainable run-rate based on your historical turnover.

Same-store growth vs. new clinic drag. New PT clinics typically take 12-18 months to reach profitability. If you opened three clinics in the last year, your reported EBITDA understates the mature earning power of the business. Sophisticated buyers will calculate a "mature clinic EBITDA" that gives credit for the ramp, which can add 1-2x to your effective multiple.

Payer Mix and Reimbursement Risk

Physical therapy reimbursement is under constant pressure, and buyers model payer mix carefully. The hierarchy of payer value, from a buyer's perspective:

Workers' compensation and auto/PIare the highest-reimbursing payers, typically 2-3x Medicare rates. Groups with 20%+ workers' comp revenue command premium multiples, but buyers will stress-test the concentration — if it's coming from one or two large employer relationships, that's a risk.

Commercial insurance (Blue Cross, Aetna, UnitedHealthcare, Cigna) is the bread and butter, reimbursing at 1.2-1.8x Medicare rates. Buyers want to see diversified commercial payer contracts with no single payer exceeding 25-30% of revenue.

Medicare reimburses at defined rates that decrease over time. The Medicare Payment Advisory Commission (MedPAC) has recommended payment reductions for outpatient therapy repeatedly. Groups with 40%+ Medicare exposure get lower multiples because buyers model continued reimbursement compression.

Medicaid is the lowest-reimbursing payer and often barely covers direct treatment costs. Heavy Medicaid exposure (25%+) will meaningfully reduce your multiple.

What Kills PT Group Value

Founder-dependent referral relationships. If your patient volume depends on the founding PT's personal relationships with orthopedic surgeons, primary care physicians, and hospital discharge planners, buyers see a business that shrinks the day you leave. The fix is to institutionalize referral relationships through your clinic directors and marketing team — but that takes 12-24 months to prove out.

Productivity gaming. Buyers and their consultants will analyze your units-per-visit data closely. If your therapists are billing 4+ units per visit consistently, it triggers compliance concerns. Medicare audits and clawbacks can create massive post-closing liabilities, and sophisticated buyers won't close without a compliance review.

Single-specialty concentration. A PT group that only treats orthopedic post-surgical patients is vulnerable to shifts in surgical protocols (think: outpatient total joints reducing PT referral windows). Diversified groups treating neuro, pelvic health, vestibular, pediatric, and sports populations are more resilient and get better multiples.

No middle management. If clinic directors report directly to the owner and there's no regional director or VP of operations layer, the business can't scale and the owner can't step back. For a multi-location healthcare group, operational infrastructure is a prerequisite for premium multiples.

Maximizing Your PT Group's Value

Invest in therapist retention before revenue growth. A clinic generating $800K with stable therapists is worth more than one generating $1M with a revolving door. Competitive compensation, mentorship programs, reasonable productivity expectations, and clinic autonomy all reduce turnover.

Build the management layer. Hire a VP of Operations or COO 18-24 months before you plan to sell. This person should be able to run the day-to-day business without you. The cost of this hire ($150K-$200K) will be returned multiple times over in your valuation.

Diversify referral sources. No single physician should account for more than 10% of your referral volume. Build relationships across orthopedics, primary care, neurology, pain management, and direct-access marketing channels.

Clean up compliance. Engage an outside compliance consultant to audit your billing practices, documentation, and supervision protocols before going to market. A clean compliance report eliminates one of the biggest deal-killers in healthcare M&A.

Open strategically, not opportunistically. New clinics should fill geographic gaps that support route density for a future acquirer. A platform buyer wants contiguous geographic coverage, not scattered clinics three hours apart.

The Bottom Line

Multi-location PT group valuation is driven by EBITDA scale, therapist retention, payer mix quality, and operational infrastructure. The market is well-established — PE firms know exactly what they want, and the pricing bands are narrow enough that you can predict your range with reasonable confidence. The groups that get 10x+ aren't just bigger; they're better-managed, better-retained, and better-prepared for life after the founder. Start building those characteristics now, and the multiple takes care of itself.

For a data-driven estimate of your PT group's value based on actual healthcare services transaction data, run a free valuation on ExitValue.ai.